Call for papers: Role of Synthetic Biology and Gene Engineering in CAR Immunotherapy

BMC Biotechnology is currently accepting submissions to a thematic series entitled ' Role of Synthetic Biology and Gene Engineering in CAR Immunotherapy'. 

Chimeric antigen receptor (CAR) T cells therapies, as a cancer immunotherapy, have provided significant benefit in treating cancer.

To present the recent advances in the theory and application of CAR immunotherapy, we invite you and/or members of your research team to provide a manuscript for this thematic series.

Your submission could take the form of original research, review, or commentary.

Deadline for submission to the collection: 30th June 2018. 

The molecular engineering of chimeric T cell receptors opens a window onto interactions between a cytotoxic T cell and a cancer cell with exciting implications for immunotherapy.​​​​​​​

New Content Item


View all articles

View all articles

Aims and scope

BMC Biotechnology is an open access, peer-reviewed journal that considers articles on the manipulation of biological macromolecules or organisms for use in experimental procedures, cellular and tissue engineering or in the pharmaceutical, agricultural biotechnology and allied industries.


  • Ying Lou, BioMed Central

Section Editors

  • Ayelet Fishman,Technion
  • Joaquim M Cabral, Instituto Superior Tecnico
  • Dennis ClaessenLeiden University​​​​​​​
  • Peter J PuntTNO Microbiology & Systems Biology/Leiden University
  • Marko RadicUniversity of Tennessee
  • John J Rossi, Beckman Research Institute City of Hope
  • Igor Stagljar, University of Toronto
  • Neal C StewartUniversity of Tennessee

Data Support Services pilot

Authors submitting to this journal can opt to use a new service that will make it easier to share research data.

Find out more